3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of 3B BlackBio Dx Ltd met on May 28, 2025 and approved audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025. Standalone revenue from operations rose to Rs. 9,052.97 lakhs in FY25 from Rs. 7,072.45 lakhs in FY24, a growth of about 28%. Standalone profit after tax jumped to Rs. 4,755.95 lakhs from Rs. 3,421.35 lakhs, with EPS at Rs. 55.51 versus Rs. 39.93. Consolidated revenue stood at Rs. 9,646.86 lakhs and consolidated PAT at Rs. 4,769.11 lakhs. The Board recommended a final dividend of 40 percent, i.e., Rs. 4.00 per equity share on a face value of Rs. 10, subject to shareholder approval at the upcoming AGM. The Board also appointed Mr. Praveen Kumar Rai as Secretarial Auditor for FY26 to FY30 and M/s Ali Jain & Sharma as Internal Auditor for FY26.
Strong double-digit growth in both revenue and profit along with a healthy dividend declaration is a positive signal for shareholders. Pending AGM approval, eligible shareholders will receive Rs. 4 per share as final dividend for FY25.